Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Blankenstein, Thomas Prof. Dr. (16) Daniel, Peter Prof. Dr. (3) Hinz, Michael Dr. (2) Kammertöns, Thomas Dr. (3) Kopp, Joachim Dr. (1) Leutz, Achim Prof. Dr. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (11) Pezzutto, Antonio Prof. Dr. (2) Scheidereit, Claus Prof. Dr. (4) Uckert, Wolfgang Prof. Dr. (4) Willimsky, Gerald Dr. (5) Wollert-Wulf, Brigitte (2) (-) Janz, Martin Dr. (7) (-) Leisegang, Matthias Prof. Dr. rer. nat. (1) (-) Biologie maligner Lymphome (7) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (1) Proteom Dynamik (9) 1999 (1) 2000 (1) (-) 2002 (1) 2003 (3) 2004 (2) (-) 2005 (2) (-) 2006 (5) 2007 (2) 2008 (2) 2009 (3) 2010 (2) 2011 (5) 2012 (2) 2013 (2) 2014 (1) 2015 (4) 2016 (2) 2017 (4) 2018 (2) 2019 (3) 2020 (5) 2021 (4) 2022 (7) 2023 (6) 2024 (1) 8 Ergebnisse: Active Filter: Janz, Martin Dr.Leisegang, Matthias Prof. Dr. rer. nat.Biologie maligner LymphomeMolekulare Immunologie und Gentherapie 200220052006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 01. Januar 2005 / Blood Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis K.R. Koh M. Janz M.Y. Mapara B. Lemke D. Stirling B. Doerken M. Zenke S. Lentzsch 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 25. August 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
01. Januar 2005 / Blood Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis K.R. Koh M. Janz M.Y. Mapara B. Lemke D. Stirling B. Doerken M. Zenke S. Lentzsch
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
25. August 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou